Azelis reports weak Q2 results with EBITA down 11%, cost-savings on track

Published 31/07/2025, 08:38
© Reuters.

Investing.com -- Azelis S.A. (BR:AZE) on Thursday reported a decrease in second-quarter EBITA of 11% to €114.8 million, in line with consensus expectations of €115.8 million, as the specialty chemicals distributor faced challenging market conditions.

The company posted flat organic revenue growth of -0.1% for the quarter, a slowdown from the 2.5% growth recorded in the first quarter of 2025. Performance varied significantly by region, with EMEA showing solid growth of 5.1% driven by both volume increases and favorable pricing.

However, this positive performance was offset by declines in other regions. The Americas saw a 3.2% drop, primarily in the personal care segment due to weaker consumer sentiment, while Asia Pacific experienced a more significant decline of 5.1%.

Profitability remained under pressure during the quarter, with gross margin falling 61 basis points to 23.7%, below consensus expectations of 24.4%.

This decline reflected a higher contribution from the Industrial Chemicals segment. EBITA margin decreased by 103 basis points to 10.8%, slightly above consensus of 10.7%, as the company faced increased costs in anticipation of a return to growth.

Despite these challenges, Azelis reported that its first-half free cash flow increased by 11% to €151.2 million. The company’s leverage ratio stood at 3.1x EBITDA, up from 2.9x in December 2024.

Azelis stated it is making good progress in aligning resources with end-market demand and expects to realize targeted cost-savings of €20 million in the second half of 2025.

In comparison, competitor IMCD (AS:IMCD) reported a 7% decrease in second-quarter EBITA to €133.2 million, which was 6% below consensus expectations of €141.7 million. IMCD’s organic revenue growth was 0.7%, also showing a slowdown from 4.2% in the first quarter.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.